Montpellier, September 19, 2024 – Quantum Surgical is launching a new clinical study for the treatment of bone tumors and metastases, assisted by the Epione® platform. Conducted in parallel at the Paoli-Calmettes Institute (Marseille) and the Hospices Civils de Lyon, the study is coordinated by Dr. Baptiste Bonnet, an interventional radiologist at Gustave Roussy (Villejuif), ranked fourth best cancer hospital in the world in 2023[1]. This study will evaluate the clinical performance and safety of the Epione platform for treating these lesions.
Although primary bone cancer is relatively rare, the development of bone metastases—often occurring several months or years after the initial cancer—is common, affecting one-third of cancer patients[2].
Specializing in medical robotics and artificial intelligence, Quantum Surgical develops the Epione technology, which enables physicians to perform safe and effective percutaneous tumor ablations. This minimally invasive treatment involves inserting one or more needles through the skin and into the tumor to destroy it.
Epione is CE marked for ablation indications in the abdomen and lung, and FDA-cleared for ablation indications in the abdomen. More than 575 patients have benefited from this curative treatment worldwide.
This new clinical study “Epibone” will assess the performance of the Epione platform to treat bone tumors and metastases, with the ultimate goal of obtaining an extension of its market approvals in Europe and the United States.
“This study is a new step in the development of Quantum Surgical, and I am pleased that it is being conducted with three of our valued partners, whose teams are well acquainted with our technology and its potential to treat more patients,” explains Bertin Nahum, CEO and Co-founder of Quantum Surgical.
“The Epibone study represents a significant advance in the evolution of robot-assisted guidance, focusing on a topic that is close to our hearts: percutaneous bone procedures. It is likely one of the most ambitious and relevant indications for the Epione robotic platform!” elaborates Dr. Baptiste Bonnet, interventional radiologist at Gustave Roussy.
Laetitia Messner, Clinical Director at Quantum Surgical, adds: “We are really eager to validate the effectiveness of Epione in treating bone lesions. Given that one-third of cancer patients suffer from bone metastases, many patients could benefit from our innovative technology.”
Epione is currently used at the Gustave Roussy Cancer Center in Villejuif, the Hospices Civils de Lyon, the Paoli-Calmettes Institute in Marseille, and the CHU Amiens-Picardie.
Epione is also used in Miami and recently available in two renowned cancer centers in the USA.
About Quantum Surgical
Quantum Surgical is a French company specializing in medical robotics and AI, co-founded in 2017 by Bertin Nahum, CEO.
With a dynamic team of over 110 employees, the company is headquartered in Montpellier, France, and has offices in Miami, Florida. Its Epione platform is dedicated to the curative and early treatment of cancers.
Quantum Surgical offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better-targeted, and less invasive treatments. Hundreds of patients have already been treated worldwide.
Quantum Surgical was awarded the prestigious Prix Galien USA in 2022, the equivalent of the Nobel Prize for biopharmaceutical research, and joined the governmental French Tech 2030 program in 2023, which supports top emerging actors in disruptive innovation.
More information: www.quantumsurgical.com
Press Contact Quantum Surgical
Stéphanie Moy
s.moy@quantumsurgical.com
Tel. : +33 (0)6 32 55 85 48
